Fintel reports that on April 2, 2025, BTIG initiated coverage of NRx Pharmaceuticals (NasdaqCM:NRXP) with a Buy ...

Fintel reports that on March 31, 2025, BTIG upgraded their outlook for Progyny (NasdaqGS:PGNY) from Neutral to Buy. Analyst ...

BTIG initiated coverage of NRx Pharmaceuticals (NRXP) with a Buy rating and $18 price target NRx Pharmaceuticals is working broadly in ...

BTIG analysts highlighted a historical trend suggesting a potential rebound for the S&P 500 (SPX) in April following a ...

The S&P 500's recent breakdown below key technical levels suggests the market’s counter-trend rally may be over, said ...

Meeting to be held in Dallas on April 8 hosted by BTIG.Don't Miss Our End of Quarter Offers: Discover the latest stocks recommended by top Wall ...

Lululemon Athletica (NASDAQ:LULU – Free Report) had its price objective decreased by BTIG Research from $470.00 to $420.00 in ...

chief market technician at financial-services firm BTIG. In a March 28 note to clients, Krinsky pointed to the S&P 500's (SP500) inability to hold the 5,670 level, a gap that had been a key ...

On Monday, BTIG analysts maintained a Neutral rating on Venus Concept Inc. (NASDAQ:VERO) after the company reported lower-than-expected Q4 revenue. Venus Concept disclosed a quarterly revenue of $ ...

BTIG Research assumed coverage on shares of Super Group (NYSE:SGHC – Free Report) in a research note published on Friday, Marketbeat Ratings reports. The firm issued a buy rating and a $9.00 ...